Novo Nordisk (NOVO) Q3 2025 earnings summary

Executive summary

• Achieved 15% sales growth and 10% operating profit growth at constant exchange rates for the first nine months of 2025, driven by strong diabetes and obesity care performance, serving 46 million people, 3 million more than last year.

• Major transformation underway, including a reduction of 9,000 positions and DKK 9 billion in restructuring costs, targeting DKK 8 billion in annual savings by 2026 and reinvestment in growth areas.

• Advanced R&D pipeline with regulatory submissions and acquisitions, including Medcera, Akero, Ameris, and Omeros, to strengthen diabetes, obesity, MASH, and rare disease portfolios.

• Strategic focus remains on diabetes, obesity, rare diseases, and expansion into cardiovascular and emerging therapy areas.

• Free cash flow reached DKK 63.9 billion, with DKK 53.2 billion returned to shareholders via dividends and share buybacks.

Financial highlights

• Sales increased to DKK 229.9 billion, up 12% in DKK and 15% at CER; US operations grew 15%, international operations 16%.

• Operating profit rose to DKK 95.9 billion, up 5% in DKK and 10% at CER, with operating margin at 41.7%.

• GLP-1 diabetes sales up 10% at CER, obesity care up 41% at CER to DKK 59.9 billion, rare disease sales up 13% at CER.

• Gross margin declined to 81.0% from 84.6% due to DKK 9 billion in restructuring costs and asset impairments.

• Free cash flow was DKK 63.9 billion, down from DKK 71.8 billion last year, mainly due to higher capital expenditures.

Outlook and guidance

• 2025 sales growth expected at 8–11% at CER, with operating profit growth at 4–7% at CER, both narrowed from previous guidance due to lower GLP-1 growth and intensifying competition.

• Free cash flow guidance lowered to DKK 20–30 billion, factoring in lower US trade receivables and reduced capital expenses.

• Capital expenditure for 2025 forecast at DKK 60 billion.

• Patent expiry and Akero acquisition expected to have low single-digit and 3% negative impacts on 2026 sales and profit growth, respectively.

• Effective tax rate anticipated at 21–23%.